Les inscriptions sont ouvertes pour notre programme de 4 mois à temps plein, à Mila, conçu spécifiquement pour les fondateurs et fondatrices de la deep tech issus de parcours d'élite en STIM. Vous avez jusqu'au 21 novembre 2026 pour appliquer!
Offert par Mila et le Forum des politiques publiques, ce programme est conçu pour outiller les décideur·euse·s et les responsables des politiques publiques à naviguer efficacement à travers les opportunités et les risques liés à l'IA. La prochaine cohorte se tiendra en anglais les 5 et 6 novembre 2026 à Ottawa.
Le processus de demandes de supervision à Mila est maintenant ouvert! Vous pouvez appliquer dès maintenant à la maitrise de recherche ou Doctorat et joindre notre grande communauté de chercheur·euse·s à Mila pour l’automne 2027. Date limite : 1er décembre 2026
Nous utilisons des témoins pour analyser le trafic et l’utilisation de notre site web, afin de personnaliser votre expérience. Vous pouvez désactiver ces technologies à tout moment, mais cela peut restreindre certaines fonctionnalités du site. Consultez notre Politique de protection de la vie privée pour en savoir plus.
Paramètre des cookies
Vous pouvez activer et désactiver les types de cookies que vous souhaitez accepter. Cependant certains choix que vous ferez pourraient affecter les services proposés sur nos sites (ex : suggestions, annonces personnalisées, etc.).
Cookies essentiels
Ces cookies sont nécessaires au fonctionnement du site et ne peuvent être désactivés. (Toujours actif)
Cookies analyse
Acceptez-vous l'utilisation de cookies pour mesurer l'audience de nos sites ?
Lecteur Multimédia
Acceptez-vous l'utilisation de cookies pour afficher et vous permettre de regarder les contenus vidéo hébergés par nos partenaires (YouTube, etc.) ?
BACKGROUND: High dose rate (HDR) brachytherapy requires clinicians to digitize catheters manually. This process is time-consuming, complex, … (voir plus)and depends heavily on clinical experience-especially in breast cancer cases, where catheters may be inserted at varying angles and orientations due to an irregular anatomy. PURPOSE: This study is the first to automate catheter digitization specifically for breast HDR brachytherapy, emphasizing the unique challenges associated with this treatment site. It also introduces a pipeline that automatically digitizes catheters, generates dwell positions, and calculates the delivered dose for new breast cancer patients. METHODS: Treatment data from 117 breast cancer patients treated with HDR brachytherapy were used. Pseudo-contours for the catheters were created from the treatment digitization points and divided into three classes: catheter body, catheter head, and catheter tip. An nnU-Net pipeline was trained to segment the pseudo-contours on treatment planning computed tomography images of 88 patients (training and validation). Then, pseudo-contours were digitized by separating the catheters into connected components. Predicted catheters with an unusual volume were flagged for manual review. A custom algorithm was designed to report and separate connected components containing colliding catheters. Finally, a spline was fitted to every separated catheter, and the tip was identified on the spline using the tip contour prediction. Dwell positions were placed from the created tip at a regular step size extracted from the DICOM plan file. Distance from each dwell position used during the clinical treatment to the fitted spline (shaft distance) was computed, as well as the distance from the treatment tip to the one identified by our pipeline. Dwell times from the clinical plan were assigned to the nearest generated dwell positions. TG-43 dose in water was computed analytically, and the absorbed dose in the medium was predicted using a published AI-based dose prediction model. Dosimetric comparison between the clinically delivered plan dose and the created automated plan dose was evaluated regarding dosimetric indices percent error. RESULTS: values in all the organs at risk, the average error remained below 5%. The pipeline execution time, including auto-contouring, digitization, and dose to medium prediction, averages 118 s, ranging from 63 to 294 s. The pipeline successfully flagged all cases where digitization was not performed correctly. CONCLUSIONS: Our pipeline is the first to automate the digitization of catheters for breast brachytherapy, as well as the first to generate dwell positions and predict corresponding AI-based absorbed dose to medium based on automatically digitized catheters. The automatically digitized catheters are in excellent agreement with the manually digitized ones while more accurately reflecting their true anatomical shape.
Objective. Treatment plan optimization in high dose rate brachytherapy often requires manual fine-tuning of penalty weights for each objecti… (voir plus)ve, which can be time-consuming and dependent on the planner's experience. To automate this process, this study used a multi-criteria approach called multi-objective Bayesian optimization with q-noisy expected hypervolume improvement as its acquisition function (MOBO-qNEHVI). Approach. The treatment plans of 13 prostate cancer patients were retrospectively imported to a research treatment planning system, RapidBrachyMTPS, where fast mixed integer optimization (FMIO) performs dwell time optimization given a set of penalty weights to deliver 15 Gy to the target volume. MOBO-qNEHVI was used to find patient-specific Pareto optimal penalty weight vectors that yield clinically acceptable dose volume histogram metrics. The relationship between the number of MOBO-qNEHVI iterations and the number of clinically acceptable plans per patient (acceptance rate) was investigated. The performance time was obtained for various parameter configurations. Main results. MOBO-qNEHVI found clinically acceptable treatment plans for all patients. With increasing the number of MOBO-qNEHVI iterations, the acceptance rate grew logarithmically while the performance time grew exponentially. Fixing the penalty weight of the tumour volume to maximum value, adding the target dose as a parameter, initiating MOBO-qNEHVI with 25 parallel sampling of FMIO, and running 6 MOBO-qNEHVI iterations found solutions that delivered 15 Gy to the hottest 95% of the clinical target volume while respecting the dose constraints to the organs at risk. The average acceptance rate for each patient was 89.74% ± 8.11%, and performance time was 66.6 ± 12.6 s. The initiation took 22.47 ± 7.57 s, and each iteration took 7.35 ± 2.45 s to find one Pareto solution.Significance. MOBO-qNEHVI combined with FMIO can automatically explore the trade-offs between treatment plan objectives in a patient specific manner within a minute. This approach can reduce the dependency of plan quality on planner’s experience and reduce dose to the organs at risk.